Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
M. Simonelli
No relevant relationships to disclose
P. A. Zucali
No relevant relationships to disclose
R. De Sanctis
No relevant relationships to disclose
E. Lorenzi
No relevant relationships to disclose
F. De Vincenzo
No relevant relationships to disclose
L. Rimassa
No relevant relationships to disclose
M. C. Tronconi
No relevant relationships to disclose
N. Personeni
No relevant relationships to disclose
G. Masci
No relevant relationships to disclose
M. Zuradelli
No relevant relationships to disclose
M. Perrino
No relevant relationships to disclose
M. Bertossi
No relevant relationships to disclose
L. Giordano
No relevant relationships to disclose
A. Santoro
No relevant relationships to disclose